Evommune shares phase 2a AD data for EVO301
The executive highlighted EVO301's Phase 2a success and initial dosing data, with plans to launch a Phase 2b trial in mid-2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed